TAF1D promotes proliferation by transcriptionally activating G2/M phase‐related genes in MYCN‐amplified neuroblastoma
Xuan Zhang,Shijia Zhan,Xiaoxing Guan,Yanli Zhang,Jie Lu,Yongbo Yu,Yaqiong Jin,Yeran Yang,Ping Chu,Enyu Hong,Hui Yang,Huimin Ren,Di Geng,Yadi Wang,Pingping Zhou,Yongli Guo,Yan Chang
DOI: https://doi.org/10.1111/cas.15815
IF: 5.7
2023-04-26
Cancer Science
Abstract:In this study, we conducted a targeted siRNA screening and identified TATA box‐binding protein‐associated factor, TAF1D, as a critical regulator of the cell cycle and proliferation in high‐risk neuroblastoma cells in vivo and in vitro. Mechanistically, we demonstrate that TAF1D knockdown downregulates the expression of a set of G2/M phase‐related genes, including the master cell cycle kinase, cyclin‐dependent kinase 1 (CDK1), and leads to G2/M arrest. Thus, our work describes a novel cell‐cycle regulatory function of TAF1D in MYCN‐amplified HR‐NB that warrants further investigation as a potential therapeutic target and biomarker for high‐risk neuroblastoma. High‐risk neuroblastoma (HR‐NB) is an aggressive childhood cancer that responds poorly to currently available therapies and is associated with only about a 50% 5‐year survival rate. MYCN amplification is a critical driver of these aggressive tumors, but so far there have not been any approved treatments to effectively treat HR‐NB by targeting MYCN or its downstream effectors. Thus, the identification of novel molecular targets and therapeutic strategies to treat children diagnosed with HR‐NB represents an urgent unmet medical need. Here, we conducted a targeted siRNA screening and identified TATA box‐binding protein‐associated factor RNA polymerase I subunit D, TAF1D, as a critical regulator of the cell cycle and proliferation in HR‐NB cells. Analysis of three independent primary NB cohorts determined that high TAF1D expression correlated with MYCN‐amplified, high‐risk disease and poor clinical outcomes. TAF1D knockdown more robustly inhibited cell proliferation in MYCN‐amplified NB cells compared with MYCN‐non‐amplified NB cells, as well as suppressed colony formation and inhibited tumor growth in a xenograft mouse model of MYCN‐amplified NB. RNA‐seq analysis revealed that TAF1D knockdown downregulates the expression of genes associated with the G2/M transition, including the master cell‐cycle regulator, cell‐cycle‐dependent kinase 1 (CDK1), resulting in cell‐cycle arrest at G2/M. Our findings demonstrate that TAF1D is a key oncogenic regulator of MYCN‐amplified HR‐NB and suggest that therapeutic targeting of TAF1D may be a viable strategy to treat HR‐NB patients by blocking cell‐cycle progression and the proliferation of tumor cells.
oncology